# Ticagrelore Alone Post PCI

> **NCT06509893** · PHASE4 · RECRUITING · sponsor: **Shiraz University of Medical Sciences** · enrollment: 5400 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** aspirin 80 mg and clopidogrel 75 mg daily
- **DRUG:** Ticagrelor 90 MG

## Key facts

- **NCT ID:** NCT06509893
- **Lead sponsor:** Shiraz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 5400 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509893, "Ticagrelore Alone Post PCI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06509893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*